xBxBio, where the fusion of multidisciplinary sciences and cutting-edge technologies unleashes unparalleled innovation and propels the drug research industry into a transformative future.
xBxBio™ LLC is a drug discovery company led by Kenneth Bean, a former FDA Quality Control and Quality Management executive at the U.S. Food & Drug Administration, and co-recipient of the prestigious National Medal of Technology and Innovation (at Biogen for contribution to Hepatitis B Vaccine- 1998. Awarded by President William J. Clinton). Its xBxBio ™ platform will enable scientists to test far more variables faster than what is available today. This will eventually lead to personalized drug development.
The company has partnered with Amazon Web Services (AWS) Data Migration Program and AWS Consulting Strategic Partner, Cloud 303 to enhance the scale of its engineering and software development operations. It has successfully completed a “proof of concept” for its technology using the AWS suite of cloud data management and analytics tools (An earlier validation of “proof of concept” was completed by an independent team of professors from Harvard Medical School and Yale University’s computer science department).
Its “patent pending” technology will improve the chance of success of drug discovery compounds by 150%, reduce 5 to 6 years off the traditional approval process, and decrease the cost of a typical 3-phase FDA clinical study by over $120 million. A McKinsey & Company study identifies the market for its services to be more than $50 billion annually. xBxBio's technology is “market ready” and the company will begin discussions with major drug and biotech companies in the near future.
Unprecedented Velocity.
Impeccable Reliability.
Powering Synergy.
Sparking Discovery.
The Future of Drug Research.
Paa
Traditional drug discovery and development efforts have become increasingly complex, lengthy, capital-intensive, and prone to high failure rates.
Our computational Software as a Service (SaaS), Platform as a Service (PaaS), and Technology as a Service (TaaS) platforms are capable of predicting critical properties of molecules with a high degree of accuracy. This critical capability enables drug discovery teams to design and selectively synthesize molecules with more optimal properties, reducing the average time and costs required to identify a development candidate and increasing the probability that a drug discovery program will enter clinical development.
Discover the range of services offered by xBxBio. We provide innovative solutions in Medical and Biotechnology manufacturing. Our services include TaaS (Technology as a Service), SaaS (Software as a Service), PaaS (Platform as a Service), and Consulting. With our expertise and cutting-edge technology, we help our clients achieve their goals and drive success in the industry.
Transform your business with our Technology as a Service (TaaS) solution. We offer state-of-the-art medical and biotechnology technologies that can be accessed on-demand. Our TaaS model allows you to leverage the latest advancements without the need for heavy investments. Stay ahead of the competition and streamline your operations with xBxBio's TaaS.
Simplify your software needs with our Software as a Service (SaaS) offering. We provide user-friendly and customizable software solutions tailored to the medical and biotechnology industry. From data management to analytics, our SaaS solutions empower you to make informed decisions and optimize your processes. Experience seamless integration and enhanced efficiency with xBxBio's SaaS.
Accelerate your product development with our Platform as a Service (PaaS) platform. xBxBio's PaaS offers a comprehensive suite of tools and resources to support your medical and biotechnology projects. Collaborate, prototype, and scale your innovations with ease. Our PaaS enables you to focus on your core competencies while we handle the infrastructure. Unlock your potential with xBxBio's PaaS.
xBxBio offers on-site deployment for organizations needing data control and security, allowing customization. Cloud deployment, hosted on xbxBio's ARX servers, offers flexibility and scalability with automatic updates and remote access. xBxBio's experts consult clients to determine the best deployment based on research and data needs, including data scientists, software engineers, and drug development specialists.
The Problem Addressed
Traditional drug discovery and development efforts have become increasingly complex, lengthy, and
capital-intensive, and are prone to high failure rates. The process involves experimental screening of existing libraries of molecules to find molecules with detectable activity, or “hit molecules,” followed by many rounds of chemical synthesis to attempt to optimize those hit molecules to a development candidate that can be advanced into clinical development...
The xBxBio Solution
Our differentiated, physics, chemistry, biology, and mathematics-based software platform will enable the discovery of high-quality, novel molecules for drug development and materials applications more rapidly, at lower cost, and with, we believe, a higher likelihood of success compared to traditional methods. We believe that we can improve the likelihood of success for compounds by 150% and that we can also reduce the cost of a typical 3 phase FDA clinical study by over $120 million, and shave 5 to 6 years off the process. We estimate the market for our services to be in excess of $25BB annually...
Computational SaaS Platform
Our computational Software as a Service (SaaS) platform is capable of predicting critical properties of molecules with a high degree of accuracy. This critical capability enables drug discovery teams to design and selectively synthesize molecules with more optimal properties, reducing the average time and costs required to identify a development candidate and increasing the probability that a drug discovery program will enter clinical development. Furthermore, we believe that development candidates with more optimized property profiles will have a higher probability of success in clinical development.